Secreted beta -Amyloid Precursor Protein Counteracts the Proapoptotic Action of Mutant Presenilin-1 by Activation of NF-kappa B and Stabilization of Calcium Homeostasis*

Qing Guo, Nic Robinson, and Mark P. MattsonDagger

From the Sanders-Brown Research Center on Aging and Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky 40536

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Mutations in the presenilin-1 (PS-1) gene account for approximately 50% of the cases of autosomal dominant, early onset, inherited forms of Alzheimer's disease (AD). PS-1 is an integral membrane protein expressed in neurons and is localized primarily in the endoplasmic reticulum (ER). PS-1 mutations may promote neuronal degeneration by altering the processing of the beta -amyloid precursor protein (APP) and/or by engaging apoptotic pathways. Alternative processing of APP in AD may increase production of neurotoxic amyloid beta -peptide (Abeta ) and reduce production of the neuroprotective alpha -secretase-derived form of APP (sAPPalpha ). In differentiated PC12 cells expressing an AD-linked PS-1 mutation (L286V), sAPPalpha activated the transcription factor NF-kappa B and prevented apoptosis induced by Abeta . Treatment of cells with kappa B decoy DNA blocked the antiapoptotic action of sAPPalpha , demonstrating the requirement for NF-kappa B activation in the cytoprotective action of sAPPalpha . Cells expressing mutant PS-1 exhibited an aberrant pattern of NF-kappa B activity following exposure to Abeta , which was characterized by enhanced early activation of NF-kappa B followed by a prolonged depression of activity. Blockade of NF-kappa B activity in cells expressing mutant PS-1 by kappa B decoy DNA was associated with enhanced Abeta -induced increases of [Ca2+]i and mitochondrial dysfunction. Treatment of cells with sAPPalpha stabilized [Ca2+]i and mitochondrial function and suppressed oxidative stress by a mechanism involving activation of NF-kappa B. Blockade of ER calcium release prevented (and stimulation of ER calcium release by thapsigargin induced) apoptosis in cells expressing mutant PS-1, suggesting a pivotal role for ER calcium release in the proapoptotic action of mutant PS-1. Finally, a role for NF-kappa B in preventing apoptosis induced by ER calcium release was demonstrated by data showing that sAPPalpha prevents thapsigargin-induced apoptosis, an effect blocked by kappa B decoy DNA. We conclude that sAPPalpha stabilizes cellular calcium homeostasis and protects neural cells against the proapoptotic action of mutant PS-1 by a mechanism involving activation of NF-kappa B. The data further suggest that PS-1 mutations result in aberrant NF-kappa B regulation that may render neurons vulnerable to apoptosis.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Alzheimer's disease (AD)1 is characterized by the accumulation of amyloid beta -peptide (Abeta ) and death of neurons in brain regions involved in learning and memory processes (1). Neuronal apoptosis (2, 3) is implicated in AD based on studies of postmortem brain tissues (4, 5) and cell culture studies showing that Abeta can induce apoptosis (6, 7). Some cases of AD are inherited in an autosomal dominant manner and are characterized by early age of onset; approximately half of these cases are caused by mutations in the presenilin-1 (PS-1) gene located on chromosome 14 (8-10). PS-1 encodes an integral membrane protein with six or eight membrane-spanning domains (11-13) and is localized in the endoplasmic reticulum (ER; Refs. 14-17). PS-1 is expressed in neurons throughout the brain (18-21) and is present in both degenerating and nondegenerating neurons in AD brain (22, 23). Consequences of PS-1 and PS-2 mutation expression in cultured cells include increased production of a long form of Abeta (Abeta -(1-42); Refs. 24 and 25), decreased choline acetyltransferase activity (26), and increased vulnerability of cells to apoptosis (27-30). The mechanism(s) whereby PS mutations sensitize neurons to apoptosis is unknown.

Links between aberrant proteolytic processing of APP and neuronal degeneration in AD are supported by considerable data (for a review, see Ref. 31). APP mutations, which account for some cases of inherited AD, may simultaneously increase production of neurotoxic forms of Abeta and decrease production of neuroprotective secreted forms of APP (sAPPalpha ). Abeta can induce neuronal apoptosis and can increase neuronal vulnerability to excitotoxicity by a mechanism involving induction of oxidative stress (32-36) and disruption of calcium homeostasis (35-39). On the other hand, sAPPalpha stabilizes neuronal calcium homeostasis and protects neurons against excitotoxic, metabolic, and oxidative insults including exposure to Abeta (40, 41).

It was recently reported that sAPPalpha induces activation of the transcription factor NF-kappa B in cultured hippocampal neurons (42). NF-kappa B exists in the cytosol as an inducible three-subunit complex consisting of the transcription factor dimer (p50 and p65) and an associated inhibitory subunit called I-kappa B (43). NF-kappa B activation occurs when I-kappa B is induced to dissociate from the complex, a process that may involve phosphorylation, proteolysis, and/or oxidative damage to I-kappa B. Recent findings suggest that NF-kappa B plays an antiapoptotic role in nonneuronal cells (44, 45) and in neurons (46-48). Agents that activate NF-kappa B (e.g. tumor necrosis factor and ceramide) can prevent cell death induced by excitotoxic, metabolic, and oxidative insults including exposure to Abeta (49, 50), whereas kappa B decoy DNA (which blocks NF-kappa B activity) enhances cell death in several paradigms (47, 48). NF-kappa B activity may be altered in vulnerable brain regions in AD patients, such that its activity is increased in neurons associated with plaque amyloid (51, 52). We now report that sAPPalpha counteracts the proapoptotic actions of mutant PS-1 by activating NF-kappa B and stabilizing calcium homeostasis. NF-kappa B appears to interrupt the apoptotic program at an early stage prior to oxyradical production and mitochondrial dysfunction. An abnormal sustained suppression of NF-kappa B activity following exposure of cells to Abeta occurred in cells overexpressing mutant (but not wild-type) PS-1, suggesting a role for this transcription factor in the pathogenic mechanism of PS-1 mutations.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

PC12 Cell Lines and Experimental Treatments-- Rat pheochromocytoma (PC12) cell lines stably expressing human wild-type PS-1 and mutant PS-1 (L286V) were established using the "Tet-off" expression system (Promega), where the expression of the transgene is under the control of a tetracycline-sensitive transactivator, as described in detail in our previous studies (28). Cells were maintained at 37 °C (5% CO2 atmosphere) in RPMI medium supplemented with 10% heat-inactivated horse serum and 5% heat-inactivated fetal bovine serum. For differentiation, cells were maintained in the presence of 50 ng/ml nerve growth factor for 14 days in RPMI containing 2% bovine serum albumin in the continued presence of 2 µg/ml tetracycline; the tetracycline was then removed for 48 h to induce PS-1 expression. Preliminary Western blot analyses demonstrated responsiveness of PS-1 expression to tetracycline withdrawal and that lines expressing wild-type and mutant PS-1 overexpressed the proteins at comparable, moderately high, levels (28); two lines overexpressing wild-type PS-1 (PS-1C3 and PS-1C7) and two lines overexpressing the L286V PS-1 mutation (PS1L286VC1 and PS1L286VC9) at similar levels were used in the present study.

Synthetic Abeta -(1-42) was synthesized at the University of Kentucky Macromolecular Analysis Facility and purified by high pressure liquid chromatography, and it was stored lyophilized; a 1 mM stock solution was prepared in sterile deionized water approximately 16 h prior to use. Immediately prior to experimental treatment, the culture medium was switched to Locke's solution, which contained 154 mM NaCl; 5.6 mM KCl, 2.3 mM CaCl2, 1.0 mM MgCl2, 3.6 mM NaHCO3, 10 mM glucose, 5 mM Hepes buffer (pH 7.2). Secreted APPalpha (sAPPalpha 695) was purified from the culture supernatant of human embryonic kidney 293 cells transfected with the corresponding cDNA constructs as described previously (40). Purity was confirmed by Western blot analysis and silver staining after SDS-polyacrylamide gel electrophoresis. Double-stranded kappa B decoy DNA was prepared by annealing complementary single strands (2 mM each) with the sequences 5'-GAGGGGACTTTCCCT-3' and 5'-AGGGAAAGTCCCCTC-3'. Nifedipine, sodium dantrolene, and thapsigargin were purchased from Sigma and prepared as 500 × stocks in ethanol.

Quantification of Apoptosis and Mitochondrial Function-- Methods for analysis of apoptosis are detailed in our previous studies (28, 36). Briefly, cells were stained with the fluorescent DNA-binding dyes Hoechst 33342 or propidium iodide, and cells were visualized under epifluorescence illumination. Cells with condensed and fragmented (apoptotic) nuclei were counted in four random × 40 fields per culture; counts were made without knowledge of cell line or treatment history. Images of propidium iodide-stained cells were acquired with a confocal laser scanning microscope (Molecular Dynamics; 488-nm excitation and 510-nm barrier filter) using a × 60 oil immersion objective. Two methods were employed to assess mitochondrial function. Mitochondrial transmembrane potential was assessed using the dye rhodamine 123 (Molecular Probes, Inc.) as described previously (53). Cultures were incubated for 30 min in RPMI 1640, containing 5 µM rhodamine 123, and were then washed with Locke's solution. Cellular fluorescence was imaged using a laser scanning confocal microscope with excitation at 488 nm and emission at 510 nm. Levels of cellular MTT reduction, a measure of mitochondrial energy charge/redox state (54), were quantified as described previously (36). Briefly, MTT solution (5 mg/ml phosphate-buffered saline) was added to cultures (1:10, MTT solution:culture medium, v/v) and allowed to incubate for 3 h. The cells were washed three times with Locke's solution and solubilized in dimethyl sulfoxide, and the absorbance (592 nm) in each well was quantified using a plate reader.

Measurements of [Ca2+]i and Cellular Peroxide Levels-- Fluorescence ratio imaging of the calcium indicator dye fura-2 was performed as described previously (37, 38). Briefly, following exposure to Abeta , cells were loaded with fura-2 (30-min incubation in the presence of 10 µM fura-2), and maintained in the presence of Abeta and other treatments during imaging. Fluorescence was imaged using a Zeiss AttoFluor system with a × 40 oil objective; the average [Ca2+]i in individual neuronal cell bodies was determined from the ratio of the fluorescence emissions obtained using two different excitation wavelengths (334 and 380 nm). The system was calibrated using solutions containing either no Ca2+ or a saturating level of Ca2+ (1 mM) using the formula [Ca2+]i = Kd[(R - Rmin)/(Rmax - R)](Fo/Fs). Relative levels of cellular peroxides were quantified in individual PC12 cells by confocal laser scanning microscope analysis using the dye 2',7'-dichlorofluorescin diacetate (Molecular Probes) as described previously (33). Briefly, cells were incubated for 50 min in the presence of 50 µM dye and were then washed three times (2 ml/wash) in Locke's solution. Images of cellular fluorescence were acquired using a confocal laser scanning microscope (Molecular Dynamics) with excitation at 488 nm and emission at 510 nm. The intensity of the laser beam and the sensitivity of the photodetector were held constant to allow quantitative comparisons of relative fluorescence intensity of cells between treatment groups. Cells were located under visible light and scanned only once with the laser to avoid artifacts associated with photo-oxidation. Fluorescence intensities in cell bodies were quantified using Molecular Dynamics "Imagespace" software.

Electrophoretic Mobility Gel Shift Assay-- These methods were similar to those described previously (46, 48). Briefly, cell extracts containing DNA-binding proteins were prepared, and gel shift assays were performed using a commercially available assay kit (Promega). Double-stranded, 32P-labeled DNA (kappa B consensus sequence 5'-AGT TGA GGG GAC TTT CCC AGG C-3'; 100,000 cpm) was added to a reaction mixture containing 5 µl nuclease-free water, 2 µl of gel shift binding 5× buffer (20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM NaCl, 0.25 mg/ml poly(DL-dC)-poly(DL-dC), and 50 mM Tris-HCl, pH 7.5) and 2 µl (5 µg) of cell extract. The reaction was allowed to proceed for 20 min at room temperature, and then 1 µl of gel loading 10× buffer (40% glycerol, 0.2% bromphenol blue, 250 mM Tris-HCl, pH 7.5) was added. Samples were separated by electrophoresis through a nondenaturing 4% acrylamide gel, and the gel was dried and exposed to x-ray film. To demonstrate the specificity of the inducible NF-kappa B complexes in PC12 cells overexpressing PS-1 mutation detected in gel shift reactions, we performed five reactions: a positive control (where the 32P-labeled specific NF-kappa B consensus oligonucleotide was included in the binding reaction), a negative control (where no DNA-binding protein extract was added in the binding reaction), a specific competition assay (where an excess of unlabeled specific competitor NF-kappa B oligonucleotide probe was included in the binding reaction), a mutant kappa B competition assay (where an excess of unlabeled mutant NF-kappa B oligonucleotide 5'-AGT TGA GGC GAC TTT CCC AGG C-3' (Santa Cruz, CA) was included in the binding reaction), and a nonspecific competition assay (where excess unlabeled noncompetitor AP2 consensus oligonucleotide 5'-GAT CGA ACT GAC CGC CCG CGG CCC GT-3' was included in the binding reaction). To further determine the specificity of the gel shift reaction and to examine the possible subunit composition of the inducible NF-kappa B complexes, we performed supershift experiments using antibody raised against p50 or p65 proteins purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-p50 antibody was rabbit IgG raised against an epitope corresponding to amino acids 350-363 within the nuclear localization signal region of human p50. The anti-p65 antibody was rabbit IgG raised against the N-terminal amino acids 3-19 of the human p65. As a control for p50 and p65 antibodies, extracts of DNA-binding proteins were also incubated in the presence of preimmune rabbit serum. Supershift experiments were performed by adding 1.0 µl of the antibody per 10 µl of reaction volume prior to the addition of 32P-labeled oligonucleotide probe, and the mixtures were incubated overnight at 4 °C. Relative levels of DNA-protein hybrids were quantified by densitometric analysis of scanned gel images using NIH Image 1.47 software.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

sAPPalpha Protects PC12 Cells Expressing Mutant PS-1 against Apoptosis Induced by Abeta -- We examined the effects of mutant PS-1 and sAPPalpha on vulnerability of PC12 cells to apoptosis induced by Abeta (Abeta -(1-42)) using two cell lines overexpressing wild-type human PS-1 (PS-1C3 and PS-1C7), two lines expressing the L286V PS-1 mutation (PS-1L286VC1 and PS-1L286VC9), a vector-transfected control line, and the untransfected parent cell line. Preliminary Western blot analysis showed that levels of overexpression of wild-type and mutant PS-1 48 h following withdrawal of tetracycline were similar in the selected cell lines under the conditions employed (data not shown; cf. Ref. 28). Basal levels of apoptosis in the various cell lines ranged from 1 to 4% (Fig. 1). In previous concentration-effect studies, we found that an Abeta -(1-42) concentration of 50 µM reliably induced a moderate level of apoptosis in untransfected PC12 cells during 24-48-h exposure periods (28, 36). Exposure to 50 µM Abeta for 48 h induced apoptosis in 30-40% of cells in control PC12 cell lines and lines expressing wild-type PS-1; apoptosis was significantly enhanced (to 60-70%) in lines expressing mutant PS-1 (Figs. 1 and 2). Mutations in APP responsible for some inherited forms of AD may promote neuronal degeneration by increasing levels of neurotoxic Abeta and/or by decreasing production of sAPPalpha , which has been shown to protect neurons against excitotoxic and oxidative insults (for a review, see Ref. 31). When cell lines were pretreated for 24 h with 10 nM sAPPalpha , there was a highly significant suppression of Abeta -induced apoptosis in both control lines and lines expressing mutant PS-1 (Fig. 1).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   Secreted APPalpha protects PC12 cells against the proapoptotic action of mutant PS-1: evidence for the involvement of NF-kappa B activation and stabilization of calcium homeostasis. The indicated lines of PC12 cells were pretreated for 24 h with sAPPalpha (10 nM) or kappa B decoy DNA (25 µM), or for 1 h with dantrolene (DTL; 10 µM) or nifedipine (Nif; 1 µM) and were then exposed to Abeta (50 µM) for 48 h, and apoptosis was quantified (see "Materials and Methods"). PC12 cell lines analyzed included untransfected cells (A), vector-transfected cells (B), two different lines overexpressing wild-type PS-1 (C and D), and two different lines overexpressing mutant PS-1 (E and F). Values are the mean and S.E. of determinations made in 4-6 separate cultures. *, p < 0.01 compared with control and sAPPalpha values. **, p < 0.01 compared with the values for cultures exposed to Abeta , Abeta plus decoy DNA, and sAPPalpha plus Abeta plus decoy DNA. For panels A-D the value for cells exposed to Abeta plus decoy DNA was significantly greater than the value for cultures exposed to Abeta alone (p < 0.05). Values for PS-1L286VC1 and PS-1L286VC9 lines exposed to Abeta , Abeta plus decoy DNA, and Abeta plus sAPPalpha plus decoy DNA were significantly greater than corresponding values in each of the other cell lines (p < 0.05) (ANOVA with Scheffe's post hoc tests).


View larger version (82K):
[in this window]
[in a new window]
 
Fig. 2.   Confocal laser scanning microscope images of PC12 cells (expressing mutant PS-1) stained with the fluorescent DNA-binding dye propidium iodide. The DNA in cells in control cultures and cultures pretreated with sAPPalpha and then exposed to Abeta for 48 h is diffusely distributed throughout the nucleus (arrowhead), whereas the DNA is condensed and fragmented 48 h following exposure to 50 µM Abeta alone and in cultures pretreated with decoy DNA plus sAPPalpha and then exposed to Abeta (arrows).

Involvement of NF-kappa B in the Antiapoptotic Action of sAPPalpha -- A variety of intercellular signals that can prevent cell death induce activation of the transcription factor NF-kappa B in neural cells including tumor necrosis factor-alpha (TNFalpha ) (46), neural growth factor (47), and sAPPalpha (42). NF-kappa B is also activated in cells exposed to a variety of insults, including Abeta , that induce oxidative stress and increase [Ca2+]i (32, 52), which may represent a stress response designed to protect the cells. In order to determine whether NF-kappa B activation mediated the antiapoptotic action of sAPPalpha in PC12 cells, we employed kappa B decoy DNA to block activation of NF-kappa B (48, 55). Whereas kappa B decoy DNA alone had no effect on basal levels of apoptosis (data not shown), it significantly enhanced Abeta -induced apoptosis and completely abolished the antiapoptotic effect of sAPPalpha (Fig. 1). We next performed gel shift analysis to measure levels of NF-kappa B activity following exposure to Abeta and sAPPalpha in the different PC12 cell lines. In agreement with a previous study (56), we observed two shifted bands representing kappa B-binding proteins in unstimulated PC12 cells (Fig. 3A). The intensity of the bands was also markedly reduced in cultures treated with 25 µM kappa B decoy DNA (Fig. 3A). Gel shift analysis showed that both Abeta and sAPPalpha induced NF-kappa B activation and that kappa B decoy DNA prevented activation of NF-kappa B by each agent (Figs. 3, B-D, and 4). The two shifted bands were specific kappa B-binding proteins, since they were eliminated by incubation with excess cold specific kappa B competitor DNA but not by cold mutant kappa B or nonspecific (AP2) competitor oligonucleotide (Fig. 3E). Supershift analysis demonstrated that the higher molecular weight band of NF-kappa B was supershifted by the p65 antibody, while the lower molecular weight band of NF-kappa B was supershifted by the p50 antibody, indicating that the higher molecular weight band was p65, while the lower molecular weight band was p50 (Fig. 3E).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of mutant PS-1 and sAPPalpha on NF-kappa B activity following exposure of PC12 cells to Abeta . A, PC12 cells were exposed for 24 h to vehicle (Control) or 25 µM kappa B decoy DNA. Cell extracts were subjected to gel shift analysis. Specificity of the protein-DNA interactions representing the shifted bands was established in samples in which excess cold competitor DNA (lane 4) or nonspecific (scrambled) DNA (lane 2) was included in the assay and by not adding cell extract to the reaction (lane 3). The arrowheads point to the shifted bands corresponding to NF-kappa B subunits, and the arrow points to the free DNA. B, PC12 cell lines (untransfected cells (top), vector-transfected cells (middle), and cells overexpressing wild-type PS-1 (bottom)) were exposed to vehicle for 4 h or to 50 µM Abeta for the indicated time periods (in the absence or presence of 25 µM kappa B decoy DNA), and cell extracts were subjected to gel shift analysis. C, autoradiograms from a gel shift analysis of cell extracts from PC12 cells expressing mutant PS-1 that had been exposed to vehicle for 4 h or to 50 µM Abeta for the indicated time periods (in the absence or presence of 25 µM kappa B decoy DNA). D, autoradiograms from a gel shift analysis of cell extracts from PC12 cells expressing mutant PS-1 that had been exposed to vehicle for 4 h (Control) or to the indicated treatments for the indicated time periods. Concentrations were as follows: Abeta , 50 µM; sAPPalpha , 10 nM; kappa B decoy DNA, 25 µM. E, PC12 cells overexpressing PS-1 L286V were stimulated for 4 h with 50 µM of Abeta , and DNA-binding proteins were extracted and subjected to EMSA and supershift EMSA. Positive Control, 32P-labeled specific NF-kappa B consensus oligonucleotide (5'-AGT TGA GGG GAC TTT CCC AGG C-3'), was included in the binding reaction); Negative Control, no DNA-binding protein extract was present in the reaction; Specific Competitor, excess unlabeled specific competitor NF-kappa B consensus oligonucleotide was included in the reaction; Mutant Competitor, an excess of unlabeled mutant NF-kappa B oligonucleotide (5'-AGT TGA GGC GAC TTT CCC AGG C-3') was included in the reaction; Nonspecific Competitor, excess unlabeled noncompetitor (AP2 consensus oligonucleotide 5'-GAT CGA ACT GAC CGC CCG CGG CCC GT-3') was included in the reaction. Supershift experiments were performed using antibodies against p50 and p65 proteins (see "Materials and Methods"). Note the higher molecular weight band of NF-kappa B was supershifted by the p65 antibody, while the lower molecular weight band of NF-kappa B was supershifted by the p50 antibody, indicating that the higher molecular weight band was p65, while the lower molecular weight band was p50. As a control for p50 and p65 antibodies, extracts were incubated in the presence of preimmune rabbit serum.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Densitometric analysis of kappa B DNA-binding activities corresponding to the upper shifted band (A and B) and the lower shifted band (C and D) (see Fig. 3). The time courses of changes in levels of each active kappa B-binding protein following exposure to 50 µM Abeta in control cultures (A and C) and in cultures pretreated for 24 h with 10 nM sAPPalpha (B and D) are shown. Values are expressed as a percentage of the level in untreated control cultures and represent the mean and S.E. of determination made in three or four separate experiments. The values for PC12 cells expressing mutant PS-1 were significantly different from the values for each of the other cell lines as follows. A, 4 h (p < 0.01), 8 h (p < 0.05), 24 h (p < 0.01), and 48 h (p < 0.05); B, 4 h (p < 0.01); C, 4 h (p < 0.001), 24 h (p < 0.01), 48 h (p < 0.01); D, 4 h, p < 0.01, 24 h (p < 0.05) (ANOVA with Scheffe's post hoc tests). Overexpression of either wild-type or mutant PS-1 did not affect basal NF-kappa B activity under normal culture conditions.

We next examined the pattern of NF-kappa B activation in response to Abeta in control PC12 cell lines and lines expressing mutant PS-1. Control cell lines and lines expressing mutant PS-1 were exposed to Abeta for different time periods, and levels of NF-kappa B activity were quantified by gel shift analysis. Marked, but transient, increases in NF-kappa B activity occurred within 4 h of exposure to Abeta in each cell line; levels of DNA binding activity of each of two different bands were increased in cells exposed to Abeta (Figs. 3 and 4). The magnitude of the early NF-kappa B induction was greater in lines expressing mutant PS-1 than in control lines, a result consistent with increased levels of oxidative stress and [Ca2+]i in cells expressing mutant PS-1 (see below). However, levels of NF-kappa B activity decreased progressively 8, 24, 48, and 72 h following exposure to Abeta in all cell lines. Notably, levels of NF-kappa B activity 24-48 h following exposure to Abeta were significantly lower in cells expressing mutant PS-1 compared with control cell lines (Figs. 3 and 4). There was a correlation between a very low level of NF-kappa B activity beginning at 8 h after Abeta treatment in the lower shifted band and 24 h post-Abeta in the upper shifted band and increased apoptosis in cells expressing mutant PS-1 (Figs. 1 and 4). Treatment of cells expressing mutant PS-1 with sAPPalpha prevented the prolonged suppression of NF-kappa B activity that occurred 24-48 h following exposure to Abeta in the absence of sAPPalpha , and, in fact, levels of NF-kappa B activity remained higher than in unstimulated control cultures (Figs. 3D and 4). Collectively, these findings suggest a role for sustained increases in NF-kappa B activity in the cytoprotective action of sAPPalpha .

Cellular Calcium Homeostasis Is Disrupted by Mutant PS-1 and Restored by sAPPalpha -- Because elevations of [Ca2+]i may mediate Abeta -induced apoptosis (34, 37, 38) and because sAPPalpha has been shown to stabilize [Ca2+]i in neurons exposed to various insults (40, 41), we examined the effects of agents that suppress calcium release from ER (dantrolene) or influx through plasma membrane voltage-dependent channels (nifedipine) on apoptosis induced by Abeta . Dantrolene and nifedipine each prevented apoptosis in control PC12 cell lines and in lines expressing mutant PS-1 (Fig. 1), consistent with roles for calcium release from ER and influx through voltage-dependent membrane channels in the apoptotic process. kappa B decoy DNA did not alter the abilities of dantrolene and nifedipine to prevent Abeta -induced apoptosis (Fig. 1).

We next measured [Ca2+]i by fluorescence ratio imaging of the calcium indicator dye fura-2 in PC12 cell lines exposed to Abeta (Fig. 5). Four hours following exposure of control and wild-type PS-1-overexpressing cell lines to Abeta , the [Ca2+]i was increased to approximately 200 nM, compared with 90-100 nM in cells not exposed to Abeta (Fig. 5A). The [Ca2+]i increase in response to Abeta was markedly enhanced in cells expressing mutant PS-1, with levels reaching 400 nM within 4 h of exposure (Fig. 5A). Pretreatment of cells with sAPPalpha resulted in a significant attenuation of Abeta -induced [Ca2+]i increases in each cell line, with the magnitude of the effect being greatest in lines expressing mutant PS-1 (Fig. 5). When cells were cotreated with kappa B decoy DNA and sAPPalpha , no attenuation of Abeta -induced elevation of [Ca2+]i was observed (Fig. 5A), suggesting that NF-kappa B mediated the [Ca2+]i-stabilizing action of sAPPalpha . Co-treatment of cells of each line with kappa B decoy DNA plus Abeta resulted in a significantly greater [Ca2+]i compared with cells exposed to Abeta alone (Fig. 5A), suggesting that NF-kappa B activation in response to Abeta played a role in stabilizing cellular calcium homeostasis. Exposure of the different cell lines (untransfected, vector-transfected, wild-type PS-1, and mutant PS-1) to kappa B decoy DNA alone caused no change in [Ca2+]i during exposures of up to 12 h (Fig. 5B). However, 24 h following exposure to kappa B decoy DNA, there was a significant 2-fold increase of [Ca2+]i in cells expressing mutant PS-1 but not in control cell lines and lines overexpressing wild-type PS-1 (Fig. 5B). The latter result suggests that basal levels of NF-kappa B activity play a role in counteracting the adverse effect of mutant PS-1 on cellular calcium homeostasis.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Secreted APPalpha suppresses the elevation of [Ca2+]i induced by Abeta in PC12 cells expressing mutant PS-1. A, the indicated cell lines were exposed to vehicle (Control) or 50 µM Abeta for 4 h; additional cultures were pretreated with 10 nM sAPPalpha (alone or in combination with 25 µM kappa B decoy DNA) prior to exposure to Abeta . The [Ca2+]i was then quantified by imaging of the calcium indicator dye fura-2. Values are the mean and S.E. of determinations made in three or four cultures (20-30 cells analyzed per culture). *, p < 0.01 compared with corresponding values for cells not exposed to Abeta . **, p < 0.01 compared with values for corresponding cell lines exposed to Abeta alone. B, the indicated cell lines were exposed to 25 µM kappa B decoy DNA, and the [Ca2+]i was quantified at the indicated time points thereafter. Values are the mean and S.E. of determinations made in three or four cultures (20-30 cells analyzed per culture). *, p < 0.01 compared with each of the other three values at that time point. Similar results were obtained in a separate experiment involving lines PS-1C7 and PS-1L286VC9.

Recent data from studies of nonneuronal cells suggest that ER calcium regulation plays a role in apoptosis in several paradigms (57, 58). Because PS-1 is located in the ER, and because dantrolene protected PC12 cells against the proapoptotic action of mutant PS-1 (Fig. 1), we determined whether sAPPalpha would protect cells against apoptosis induced by thapsigargin, an agent known to induce apoptosis by selectively inhibiting the ER Ca2+-ATPase (59). Pretreatment with sAPPalpha resulted in a significant reduction in apoptosis induced by thapsigargin in each control cell line and in lines expressing mutant PS-1 (Fig. 6). The protective effect of sAPPalpha against thapsigargin-induced apoptosis was abolished in cultures co-treated with kappa B decoy DNA (data not shown) indicating a necessary role for NF-kappa B activation in suppression of apoptosis induced by ER calcium release.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 6.   Secreted APPalpha suppresses apoptosis induced by thapsigargin in PC12 cells expressing mutant PS-1. The indicated cell lines were exposed to vehicle (Control) or 5 µM thapsigargin (Thaps) for 24 h; some cultures were pretreated for 24 h with 10 nM sAPPalpha prior to exposure to thapsigargin. Cells were then stained with Hoechst dye, and numbers of apoptotic cells in each culture were quantified. Values are the mean and S.E. of determinations made in three or four cultures. *, p < 0.01 compared with corresponding values for untransfected (untransf), vector, PS-1C3, and PS-1C7 lines. **, p < 0.01 compared with values for corresponding cell lines exposed to thapsigargin alone.

Enhanced Mitochondrial Dysfunction and Oxidative Stress in PC12 Cells Expressing Mutant PS-1: Protection by sAPPalpha -- Mitochondrial alterations, including a decrease in mitochondrial transmembrane potential and energy charge/redox state, have been identified as being central to the effector phase of apoptosis (3) and may contribute to the neurotoxic action of Abeta (36, 54). Exposure of PC12 cells to Abeta for 4 h resulted in decreases in levels of mitochondrial membrane potential, as quantified using the fluorescent probe rhodamine 123 (Fig. 7A). The decrease in rhodamine 123 fluorescence was significantly greater in cells expressing mutant PS-1 compared with control cell lines and lines overexpressing wild-type PS-1 (Fig. 7A). Pretreatment of cultures with sAPPalpha prior to exposure to Abeta resulted in a significant attenuation of the decrease in transmembrane potential, which was particularly pronounced in cell lines expressing mutant PS-1 (Fig. 7, A and C). kappa B decoy DNA suppressed the ability of sAPPalpha to prevent Abeta -induced decrease in rhodamine 123 fluorescence (Fig. 7A) and enhanced the decrease in rhodamine 123 fluorescence induced by Abeta . Exposure of the different cell lines to kappa B decoy DNA alone caused no change in rhodamine 123 fluorescence during exposures of up to 12 h (Fig. 7B). However, 24 h following exposure to kappa B decoy DNA, there was a significant decrease in mitochondrial transmembrane potential in cells expressing mutant PS-1 but not in control cell lines and lines overexpressing wild-type PS-1 (Fig. 7B). The latter result suggests that basal levels of NF-kappa B activity play a role in counteracting an adverse effect of mutant PS-1 on mitochondrial function. In parallel experiments, we quantified levels of MTT reduction, a measure of mitochondrial energy charge/redox state (54), in the different cell lines following exposure to Abeta in the presence or absence of sAPPalpha and/or kappa B decoy DNA. Exposure of PC12 cells to Abeta for 4 h resulted in a decrease in the level of MTT reduction that was significantly greater in cells expressing mutant PS-1 compared with control cell lines; pretreatment with sAPPalpha resulted in a significant attenuation of Abeta -induced decrease in MTT reduction, and this action of sAPPalpha was largely blocked by kappa B decoy DNA (data not shown).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 7.   Secreted APPalpha protects against Abeta -induced decrease in mitochondrial transmembrane potential by a mechanism involving activation of NF-kappa B. A, the indicated lines of PC12 cells were pretreated for 24 h with sAPPalpha (10 nM) or kappa B decoy DNA (25 µM) in the absence or presence of sAPPalpha and were then exposed to Abeta (50 µM) for 4 h. Levels of rhodamine 123 fluorescence were then quantified (see "Materials and Methods"). Values are the mean and S.E. of determinations made in four separate cultures (25-35 cells analyzed per culture). *, p < 0.01 compared with the control value. **, p < 0.01 compared with the corresponding values for untransfected, vector-transfected, PS-1C3, and PS-1C7 cell lines. (ANOVA with Scheffe's post-hoc tests). B, the indicated cell lines were exposed to 25 µM kappa B decoy DNA, and levels of rhodamine 123 fluorescence were quantified at the indicated time points thereafter. Values are the mean and S.E. of determinations made in three or four cultures (25-35 cells analyzed per culture). *, p < 0.01 compared with each of the other three values at that time point (ANOVA with Scheffe's post hoc tests). Similar results were obtained in a separate experiment involving lines PS-1C7 and PS-1L286VC9. C, confocal laser scanning microscope images of rhodamine 123 fluorescence in PC12 cells expressing mutant PS-1. Cultures were pretreated for 24 h with 0.2% saline or 10 nM sAPPalpha and were then exposed to either 0.5% water (control and sAPPalpha ) or 50 µM Abeta -(1-42) for 4 h. Relative levels of rhodamine 123 fluorescence are indicated by the scale bar (lower right). Note that Abeta caused a marked decrease in levels of rhodamine 123 fluorescence, which was attenuated in cells pretreated with sAPPalpha .

Previous studies showed that Abeta induces oxidative stress in cultured neurons (32-36) and that this action of Abeta is enhanced in PC12 cells expressing mutant PS-1 (28). In order to determine whether sAPPalpha modifies levels of oxidative stress and if NF-kappa B is involved, we measured relative levels of cellular peroxides using the fluorescent probe DCF (33). Exposure of PC12 cells to Abeta for 4 h resulted in an increase in DCF fluorescence that was significantly greater in cells expressing mutant PS-1 compared with control cell lines and lines overexpressing wild-type PS-1 (Fig. 8A). The Abeta -induced increase in DCF fluorescence was blocked in cells pretreated with sAPPalpha (Fig. 8). No suppression of Abeta -induced DCF fluorescence occurred in cultures cotreated with kappa B decoy DNA and sAPPalpha (data not shown).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 8.   Secreted APPalpha attenuates Abeta -induced peroxide accumulation in PC12 cells expressing mutant PS-1. A, levels of DCF fluorescence, a measure of cellular peroxide levels, were quantified in PC12 cells of the indicated lines. Cultures were exposed for 4 h to either vehicle (0.5% water) or 50 µM Abeta alone or in the presence of 10 nM sAPPalpha (sAPPalpha was added to the cultures 24 h prior to exposure to Abeta ). Values are the mean and S.E. of determinations made in three or four separate cultures (20-30 cells assessed per culture). *, p < 0.01 compared with value for corresponding cell line exposed to vehicle and to sAPP plus Abeta . **, p < 0.001 compared with the value for the corresponding cell line exposed to vehicle and p < 0.01 compared with values for control cell lines (untransfected and vector-transfected lines and lines overexpressing wild-type PS-1) exposed to Abeta . ***, p < 0.01 compared with corresponding cell lines exposed to Abeta alone (ANOVA with Scheffe's post hoc tests). B, confocal laser scanning microscope images of DCF fluorescence in PC12 cells expressing mutant PS-1. Cultures were pretreated for 24 h with 0.2% saline or 10 nM sAPPalpha and were then exposed to either 0.5% water (control and sAPPalpha ) or 50 µM Abeta -(1-42) for 4 h. Relative levels of DCF fluorescence are indicated by the scale bar (lower right). Note that Abeta caused a marked increase in levels of DCF fluorescence, which was much less pronounced in cells pretreated with sAPPalpha .

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The present findings demonstrate that sAPPalpha can protect PC12 cells against the proapoptotic action of mutant PS-1 by a mechanism involving activation of NF-kappa B, stabilization of calcium homeostasis and mitochondrial function, and suppression of oxidative stress. Recent studies of tumor cells (44, 45, 60) and cultured embryonic rat hippocampal neurons (48) have shown that activation of NF-kappa B (in response to TNFalpha ) can prevent apoptosis induced by several different insults including exposure to oxidative insults. We found that sAPPalpha induces NF-kappa B activation in PC12 cells and protects them from being killed by Abeta . The cytoprotective effect of sAPPalpha was largely prevented by co-treatment with kappa B decoy DNA, a result that provides evidence for a cause-effect relationship between activation of NF-kappa B and prevention of apoptosis. The enhancement of Abeta -induced apoptosis in PC12 cells overexpressing mutant human PS-1 was abrogated in cultures pretreated with sAPPalpha , an effect blocked by kappa B-decoy DNA. Previous studies have shown that the mechanism whereby Abeta damages and kills neurons involves induction of oxidative stress, disruption of calcium homeostasis, and mitochondrial dysfunction (for a review, see Ref. 31). We found that Abeta caused increases of [Ca2+]i and peroxide levels and induced depolarization of the mitochondrial membrane and that these actions of Abeta were each exacerbated in cells overexpressing mutant but not wild-type PS-1. PC12 cells pretreated with sAPPalpha , including lines expressing mutant PS-1, were able to maintain [Ca2+]i, peroxide levels, and mitochondrial transmembrane potential at nearly normal levels following exposure to Abeta . The ability of kappa B decoy DNA to counteract the stabilizing effect of sAPPalpha on [Ca2+]i, peroxide levels, and mitochondrial transmembrane potential indicates a central role for NF-kappa B in the antiapoptotic mechanism of action of sAPPalpha .

Gel shift analyses of NF-kappa B activation following exposure of PC12 cells to Abeta revealed differences in the pattern of NF-kappa B activity in cells overexpressing mutant PS-1 compared with cells overexpressing wild-type PS-1 and control cell lines. A striking consequence of mutant PS-1 expression was a sustained suppression of NF-kappa B activity, which was evident as early as 8 h following exposure of cells to Abeta , which was correlated with increased apoptosis measured 48 h following exposure to Abeta . In light of recent data showing that activation of NF-kappa B in cells exposed to apoptotic stimuli suppresses cell death (44-46, 48, 60), our findings suggest that the sustained suppression of NF-kappa B activity plays a role in the proapoptotic action of mutant PS-1. However, because the apoptotic process was enhanced in cells expressing mutant PS-1, we cannot completely rule out the possibility that the depressed NF-kappa B activity in cells expressing mutant PS-1 was a consequence of early events in the apoptotic process. Nevertheless, the ability of sAPPalpha to prevent both the delayed suppression of NF-kappa B activity and apoptosis in cells expressing mutant PS-1 and the ability of kappa B decoy DNA to block these effects of sAPPalpha support a role for suppression of NF-kappa B activity in the pathogenic mechanism of PS-1 mutations. The enhanced activation of NF-kappa B during the first 4 h following exposure to Abeta in cells expressing mutant PS-1 probably reflects the enhanced [Ca2+]i and oxidative stress documented in our calcium imaging and DCF fluorescence assays. Indeed, both calcium and hydrogen peroxide are known to be potent activators of NF-kappa B in many cell types including neurons (61-63). When taken together with the data showing that kappa B decoy DNA enhanced Abeta -induced cell death, the enhanced short term activation of NF-kappa B in PC12 cells expressing mutant PS-1 is clearly not involved in the enhanced vulnerability of these cells to apoptosis induced by Abeta and may represent a self-defense mechanism of the cells.

The gene targets of NF-kappa B that mediate cellular resistance to apoptosis have not been firmly established. However, two candidates are Mn-superoxide dismutase and the calcium-binding protein calbindin D28k. Both Mn-superoxide dismutase and calbindin D28k are induced by TNFalpha and ceramide in cultured embryonic rat hippocampal neurons (48, 49), and overexpression of calbindin D28k (64) and Mn-superoxide dismutase (65) in cultured neurons protects them from being killed by oxidative and metabolic apoptotic insults. Moreover, it was recently shown that kappa B decoy DNA blocks both induction of Mn-superoxide dismutase expression and resistance to apoptosis in hippocampal neurons treated with TNFalpha (48), strongly suggesting a role for this antioxidant enzyme in the neuroprotective actions of NF-kappa B activation. The evidence that Abeta toxicity in neurons involves both oxidative stress and elevation of [Ca2+]i (31) is consistent with a role for NF-kappa B-mediated regulation of expression of genes involved in regulating calcium homeostasis and free radical metabolism in the cytoprotective actions of sAPPalpha documented in the present study.

The ability of dantrolene and nifedipine to protect PC12 cells against the proapoptotic action of mutant PS-1 suggests pivotal roles of calcium release from ER and influx through voltage-dependent channels in the pathogenic mechanism of PS-1 mutations. Consistent with this interpretation are recent data showing that overexpression of the antiapoptotic gene product Bcl-2 stabilizes [Ca2+]i in PC12 cells expressing mutant PS-1 following exposure to thapsigargin (28) or Abeta .2 Bcl-2 also suppresses oxidative stress and apoptosis induced by trophic factor withdrawal in cells expressing mutant PS-1 (28). In nonneuronal cells, Bcl-2's antiapoptotic actions have been linked to suppression of ER calcium release (59). We found that the elevation of [Ca2+]i and apoptosis induced by either Abeta or thapsigargin was enhanced in cells expressing mutant PS-1. Our data therefore suggest that aberrant ER calcium regulation plays a central role in Abeta -induced apoptosis and that PS-1 mutations may promote apoptosis by enhancing ER calcium release. sAPPalpha stabilized [Ca2+]i and suppressed Abeta - and thapsigargin-induced apoptosis in cells expressing mutant PS-1. Stabilization of calcium homeostasis in cells treated with sAPPalpha was correlated with maintenance of NF-kappa B activity and mitochondrial function, consistent with the ability of well-known activators of NF-kappa B such as TNFalpha to stabilize [Ca2+]i (46, 48).

Studies of brain tissue and cultured fibroblasts from AD patients have provided evidence for perturbed calcium homeostasis in AD. Examples include the following: 1) calcium-dependent protease activity is increased in degenerating neurons in AD brain tissue (66); 2) levels of acylphosphatase, an enzyme that modulates the activity of the ER Ca2+-ATPase, are increased in fibroblasts from patients bearing PS-1 mutations (67); 3) Ca2+ release from ER in response to agonists linked to the inositol 1,4,5-trisphosphate pathway is increased in fibroblasts from carriers of PS-1 mutations (68); and 4) levels of inositol 1,4,5-trisphosphate binding to ER membranes were reported to be decreased in cerebral cortical tissue from sporadic AD patients (69). When taken together with data showing altered levels of NF-kappa B immunoreactivity and activity in neurons in vulnerable regions of AD patients (50, 51, 70), our findings suggest mechanistic links between disruption of ER calcium homeostasis, NF-kappa B activity, and neuronal apoptosis in AD. The present findings also identify systems regulating ER calcium homeostasis (e.g. inositol 1,4,5-trisphosphate receptors and Ca2+-ATPases), NF-kappa B activity (e.g. upstream regulators, NF-kappa B subunits, and NF-kappa B-responsive genes), and sAPPalpha production (e.g. secretases) as potential targets for therapeutic intervention in AD.

In addition to perturbed calcium homeostasis, accumulating data strongly suggest major contributions of oxidative stress and mitochondrial dysfunction to the pathogenesis of neuronal degeneration in AD (for a review, see Refs. 71-73). Aberrant processing of APP may promote neurodegeneration by increasing levels of neurotoxic forms of Abeta , which induce oxidative stress and disrupt calcium homeostasis, and/or by decreasing production of sAPPalpha , which exhibits neuroprotective activity (for a review, see Ref. 31). Our data suggest that, by enhancing levels of oxidative stress and promoting mitochondrial dysfunction, PS-1 mutations may sensitize neurons to Abeta -induced apoptosis. Levels of rhodamine 123 fluorescence and MTT reduction (measures of mitochondrial transmembrane potential and energy charge/redox state, respectively) were significantly decreased in PC12 cell lines expressing mutant PS-1 following exposure to Abeta compared with vector-transfected lines and lines overexpressing wild-type PS-1. In addition, levels of DCF fluorescence (a measure of cellular peroxide levels) were significantly increased in cells exposed to Abeta , an effect exacerbated by mutant PS-1. Activation of NF-kappa B appears to play an important role in suppressing oxyradical production and preserving mitochondrial function in cells exposed to Abeta , because treatment of cells with kappa B decoy DNA enhanced the Abeta -induced oxyradical accumulation and mitochondrial dysfunction and completely blocked the protective effect of sAPPalpha . Oxyradical stress and mitochondrial dysfunction in our paradigm may result from perturbed cellular calcium homeostasis, because elevation of [Ca2+]i induced by Abeta was correlated with increased oxyradical levels and mitochondrial impairment and because agents that block calcium release from ER (dantrolene) or influx through voltage-dependent calcium channels (nifedipine) suppressed oxyradical accumulation and mitochondrial dysfunction (28).2 Moreover, sAPPalpha largely prevented Abeta -induced elevations of [Ca2+]i and peroxide levels and stabilized mitochondrial transmembrane potential in cells expressing mutant PS-1; sAPPalpha also protected the cells against thapsigargin-induced apoptosis. Collectively, the data suggest that sAPPalpha prevents apoptosis by stabilizing calcium homeostasis, suppressing oxyradical production, and preserving mitochondrial function.

Additional mechanisms whereby presenilin mutations may promote apoptosis are suggested by recent studies. For example, Kim and co-workers (74) reported that PS-1 and PS-2 are cleaved by a caspase-3 family protease in a neuroglial cell line induced to undergo apoptosis. Apoptosis induced by Abeta in neurons is blocked by inhibitors of caspases, a family of proteins believed to play important roles in the effector phase of apoptosis (64, 75). Caspase inhibitors also block apoptosis in PC12 cells expressing mutant PS-1.2 However, it is not known whether cleavage of PSs by caspases is mechanistically involved in apoptosis or is a consequence of the apoptotic process. Interactions of presenilins with APP have been reported (76, 77) and might play indirect roles in promoting neuronal apoptosis. Enzymatic processing of APP is altered in AD such that levels of Abeta production (particularly the Abeta -(1-42) form) are increased and levels of sAPPalpha are decreased. Levels of Abeta -(1-42) production are increased in cultured cells transfected with mutant presenilins, in transgenic mice expressing mutant PS-1, and in cultured fibroblasts from carriers of PS mutations (24, 78). It is unclear how presenilin mutations alter APP processing, but one possibility is that the altered processing is secondary to increased levels of cellular stress. In support of this hypothesis, we have shown that PS-1 mutations destabilize calcium homeostasis and enhance oxidative and metabolic stress in PC12 cells (Refs. 27 and 28 and this study), and other laboratories have shown that sustained elevations of [Ca2+]i (79) and metabolic/oxidative stress (80) shift APP processing in favor of increased Abeta production. Prior studies have shown that enzymatic processing of APP is altered in AD such that there is reduced cleavage at the alpha -secretase site and increased cleavage at the beta - and gamma -secretase sites (for a review, see Refs. 1 and 31). It is therefore likely that the increased Abeta production in cells expressing presenilin mutations is accompanied by reduced levels of sAPPalpha , and, indeed, there is evidence that sAPPalpha levels are decreased in the cerebrospinal fluid of AD patients (81, 82), although data on sAPPalpha levels in carriers of presenilin mutations have not yet been reported. Because sAPPalpha is approximately 100-fold more potent than sAPPbeta in protecting cultured neurons against excitotoxic and oxidative insults (41), it is reasonable to consider that decreased levels of sAPPalpha contribute to the proapoptotic actions of mutant PS-1. Consistent with this possibility, our data show that sAPPalpha is very effective in protecting PC12 cells expressing mutant PS-1 against apoptosis induced by Abeta .

    ACKNOWLEDGEMENTS

We thank W. Fu, H. Luo, and R. Pelphrey for technical assistance and K. Furukawa and I. Kruman for helpful discussions.

    FOOTNOTES

* This work was supported by NINDS and NIA (National Institutes of Health) Grants AG14554, NS35253, and AG05144 (to M. P. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: 211 Sanders-Brown Bldg., University of Kentucky, Lexington, KY 40536-0230. Tel.: 606-257-6040; Fax: 606-323-2866; E-mail: mmattson{at}aging.coa.uky.edu.

1 The abbreviations used are: AD, Alzheimer's disease; Abeta , amyloid beta -peptide; PS, presenilin; ER, endoplasmic reticulum; APP, beta -amyloid precursor protein; sAPPalpha and sAPPbeta , alpha - and beta -secretase-derived form of APP, respectively; DCF, 2,7-dichlorofluorescin diacetate; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TNFalpha , tumor necrosis factor-alpha .

2 Q. Guo and M. P. Mattson, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Selkoe, D. J. (1994) Annu. Rev. Cell Biol. 10, 373-403[CrossRef]
  2. Bredesen, D. E. (1995) Ann. Neurol. 38, 839-851[Medline] [Order article via Infotrieve]
  3. Kroemer, G., Zamzami, N., and Susin, S. A. (1997) Immunol. Today 18, 44-51[CrossRef][Medline] [Order article via Infotrieve]
  4. Su, J. H., Anderson, A. J., Cummings, B., and Cotman, C. W. (1994) Neuroreport 5, 2529-2533[Medline] [Order article via Infotrieve]
  5. Smale, G., Nichols, N. R., and Brady, D. R. (1995) Exp. Neurol. 133, 225-230[CrossRef][Medline] [Order article via Infotrieve]
  6. Forloni, G., Chiesa, R., Smiroldo, S., and Verga, L. (1993) Neuroreport 4, 523-526[Medline] [Order article via Infotrieve]
  7. Loo, D. T., Copani, A., Pike, C. J., Whittemore, E. R., Walencewicz, A. J., and Cotman, C. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7951-7955[Abstract/Free Full Text]
  8. Clark, R. F., Hutton, M., Fuldner, R., Froelich, S., Karran, E., Talbot, C., Crook, R., Lendon, C., Prihar, G., He, C., Korenblat, K., Martinez, A., Wragg, M., Busfield, F., Behrens, M. J., Myers, A., Norton, J., Morris, J., Mehta, N., Pearson, C., Lincoln, S., Baker, M., Duff, K., Zehr, C., Perez-Tur, J., Houlden, H., Ruiz, A., Ossa, J., Lopera, F., Arcos, M., Madrigal, L., Collinge, J., Humphreys, C., Ashworth, A., Sarner, S., Fox, N., Harvey, R., Kennedy, A., Roques, P., Cline, R. T., Phillips, C. A., Venter, J. C., Forsell, L., Axelman, K., Lilius, L., Johnston, J., Cowburn, R., Vitanen, M., Winblad, B., Kosik, K., Haltia, M., Poyhonen, M., Dickson, D., Mann, D., Neary, D., Snowden, J., Lantos, P., Lannfelt, L., Rossor, M., Roberts, G. W., Adams, M. D., Hardy, J., and Goate, A. (1995) Nat. Genet. 11, 219-222[Medline] [Order article via Infotrieve]
  9. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J-F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sansequ, P., Polinsky, R. J., Wasco, W., Da Silva, H. A. R., Haines, J. L., Pericak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommens, J. M., and St. George-Hyslop, P. H. (1995) Nature 375, 754-760[CrossRef][Medline] [Order article via Infotrieve]
  10. Hardy, J. (1997) Trends Neurosci. 20, 154-159[CrossRef][Medline] [Order article via Infotrieve]
  11. Doan, A., Thinakaran, G., Borchelt, D. R., Slunt, H. H., Ratovitsky, T., Podlinsy, M., Selkoe, D. J., Seeger, M., Gandy, S. E., Price, D. L., and Sisodia, S. S. (1996) Neuron 17, 1023-1030[Medline] [Order article via Infotrieve]
  12. Li, X., and Greenwald, I. (1996) Neuron 17, 1015-1021[Medline] [Order article via Infotrieve]
  13. Lehmann, S., Chiesa, R., and Harris, D. A. (1997) J. Biol. Chem. 272, 12047-12051[Abstract/Free Full Text]
  14. Kovacs, D. M., Fausett, H. J., Page, K. J., Kim, T-W., Moir, R. D., Merriam, D. E., Hollister, R. D., Hallmark, O. G., Mancini, R., Felsenstein, K. M., Hyman, B. T., Tanzi, R. E., and Wasco, W. (1996) Nat. Med. 2, 224-229[Medline] [Order article via Infotrieve]
  15. Walter, J., Capell, A., Grunberg, J., Pesold, B., Schindzielorz, A., Prior, R., Podlinsy, M. B., Fraser, P., St. George-Hyslop, P., Selkoe, D. J., and Haass, C. (1996) Mol. Med. 2, 673-691[Medline] [Order article via Infotrieve]
  16. Busciglio, J., Hartmann, H., Lorenzo, A., Wong, C., Baumann, K., Sommer, B., Staufenbiel, M., and Yankner, B. A. (1997) J. Neurosci. 17, 5101-5107[Abstract/Free Full Text]
  17. Lah, J. J., Heilman, C. J., Nash, N. R., Rees, H. D., Yi, H., Counts, S. E., and Levey, A. I. (1997) J. Neurosci. 17, 1971-1980[Abstract/Free Full Text]
  18. Cook, D. B., Sung, J. C., Golde, T. E., Felsenstein, K. M., Wojczyk, B. S., Tanzi, R. E., Trojanowski, J. Q., Lee, V. M. Y., and Doms, R. W. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9223-9228[Abstract/Free Full Text]
  19. Cribbs, D. H., Chen, L., Bendle, S. M., and La Ferla, F. M. (1996) Am. J. Pathol. 148, 1797-1806[Abstract]
  20. Elder, G. A., Tezapsidis, N., Carter, J., Shioi, J,., Bouras, C., Li, D., Johnston, J., Efthimiopoulos, S., Friedrich, V., and Robakis, N. K. (1996) J. Neurosci. Res. 45, 308-320[CrossRef][Medline] [Order article via Infotrieve]
  21. Lee, M. K., Slunt, H. H., Martin, L. J., Thinakaran, G., Kim, G., Gandy, S. E., Seeger, M., Koo, E., Price, D. L., and Sisodia, S. S. (1996) J. Neurosci. 16, 7513-7525[Abstract/Free Full Text]
  22. Murphy, G. M., Forno, L. S., Ellis, W. G., Nochlin, D., Levy-Lahad, E., Poorkaj, P., Bird, T. D., Jiang, Z., and Cordell, B. (1996) Am. J. Pathol. 149, 1839-1846[Abstract]
  23. Giannakopoulos, P., Bouras, C., Kovari, E., Shioi, J., Tezapsidis, N., Hof, P. R., and Robakis, N. K. (1997) Am. J. Pathol. 150, 429-436[Abstract]
  24. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., and Younkin, S. (1996) Nature Med. 2, 864-870[Medline] [Order article via Infotrieve]
  25. Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C-M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G., and Sisodia, S. S. (1996) Neuron 17, 1005-1013[Medline] [Order article via Infotrieve]
  26. Pedersen, W., Guo, Q., Hartman, B. K., and Mattson, M. P. (1997) J. Biol. Chem. 272, 22397-22400[Abstract/Free Full Text]
  27. Guo, Q., Furukawa, K., Sopher, B. L., Pham, D. G., Xie, J., Robinson, N., Martin, G. M., and Mattson, M. P. (1996) Neuroreport 8, 379-383[Medline] [Order article via Infotrieve]
  28. Guo, Q., Sopher, B. L., Furukawa, K., Pham, D. G., Robinson, N., Martin, G. M., and Mattson, M. P. (1997) J. Neurosci. 17, 4212-4222[Abstract/Free Full Text]
  29. Wolozin, B., Iwasaki, K., Vito, P., Ganjei, J. K., Lacana, E., Sunderland, T., Zhao, B., Kusiak, J. W., Wasco, W., and D'Adamio, L. (1996) Science 274, 1710-1713[Abstract/Free Full Text]
  30. Janicki, S., and Monteiro, M. (1997) J. Cell Biol. 139, 485-495[Abstract/Free Full Text]
  31. Mattson, M. P. (1997) Physiol. Rev. 77, 1081-1132[Abstract/Free Full Text]
  32. Behl, C., Davis, J. B., Lesley, R., and Schubert, D. (1994) Cell 77, 817-827[Medline] [Order article via Infotrieve]
  33. Goodman, Y., and Mattson, M. P. (1994) Exp. Neurol. 128, 1-12[CrossRef][Medline] [Order article via Infotrieve]
  34. Mark, R. J., Hensley, K., Butterfield, D. A., and Mattson, M. P. (1995) J. Neurosci. 15, 6239-6249[Abstract]
  35. Mark, R. J., Lovell, M. A., Markesbery, W. R., Uchida, K., and Mattson, M. P. (1997) J. Neurochem. 68, 255-264[Medline] [Order article via Infotrieve]
  36. Kruman, I., Bruce-Keller, A. J., Bredesen, D. E., Waeg, G., and Mattson, M. P. (1997) J. Neurosci. 17, 5089-5100[Abstract/Free Full Text]
  37. Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R. E. (1992) J. Neurosci. 12, 376-389[Abstract]
  38. Mattson, M. P., Tomaselli, K., and Rydel, R. E. (1993) Brain Res. 621, 35-49[CrossRef][Medline] [Order article via Infotrieve]
  39. Fukuyama, R., Wadhwani, K. C., Galdzicki, Z., Rapoport, S. I., and Ehrenstein, G. (1994) Brain Res. 667, 269-272[Medline] [Order article via Infotrieve]
  40. Mattson, M. P., Cheng, B., Culwell, A., Esch, F., Lieberburg, I., and Rydel, R. E. (1993) Neuron 10, 243-254[Medline] [Order article via Infotrieve]
  41. Furukawa, K., Sopher, B. L., Rydel, R. E., Begley, J. G., Pham, D. G., Martin, G. M., Fox, M., and Mattson, M. P. (1996) J. Neurochem. 67, 1882-1896[Medline] [Order article via Infotrieve]
  42. Barger, S. W., and Mattson, M. P. (1996) Mol. Brain Res. 40, 116-126[Medline] [Order article via Infotrieve]
  43. Liou, H. C., and Baltimore, D. (1993) Curr. Opin. Cell Biol. 5, 477-487[Medline] [Order article via Infotrieve]
  44. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  45. Wu, M., Lee, H., Bellas, R. E., Schauer, S. L., Arsura, M., Katz, D., Fitzgerald, M. F., Rothstein, T. L., Sherr, D. H., and Sonenshein, G. E. (1996) EMBO J. 15, 4682-4690[Abstract]
  46. Barger, S. W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J., and Mattson, M. P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9328-9332[Abstract]
  47. Taglialatela, G., Robinson, R., and Perez-Polo, J. R. (1997) J. Neurosci. Res. 47, 155-162[CrossRef][Medline] [Order article via Infotrieve]
  48. Mattson, M. P., Goodman, Y., Luo, H., Fu, W., and Furukawa, K. (1997) J. Neurosci. Res. 49, 681-697[CrossRef][Medline] [Order article via Infotrieve]
  49. Cheng, B., Christakos, S., and Mattson, M. P. (1994) Neuron 12, 139-153[Medline] [Order article via Infotrieve]
  50. Goodman, Y., and Mattson, M. P. (1996) J. Neurochem. 66, 869-872[Medline] [Order article via Infotrieve]
  51. Terai, K., Matsuo, A., and McGeer, P. L. (1996) Brain Res. 735, 159-168[CrossRef][Medline] [Order article via Infotrieve]
  52. Kaltschmidt, B., Uherek, M., Volk, B., Baeuerle, P. A., and Kaltschmidt, C. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2642-2647[Abstract/Free Full Text]
  53. Mattson, M. P., Zhang, Y., and Bose, S. (1993) Exp. Neurol. 121, 1-13[CrossRef][Medline] [Order article via Infotrieve].
  54. Shearman, M. S., Ragan, C. I., and Iversen, L. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1470-1474[Abstract]
  55. Tanaka, H., Vickart, P., Bertrand, J. R., Rayner, B., Morvan, F., Imbach, J. L., Paulin, D., and Malvy, C. (1994) Nucleic Acids Res. 22, 3069-3074[Abstract]
  56. Tong, L., and Perez-Polo, J. R. (1996) J. Neurosci. Res. 45, 1-12[CrossRef][Medline] [Order article via Infotrieve]
  57. Khan, A. A., Soloski, M. J., Sharp, A. H., Schilling, G., Sabatini, D. M., Li, S. H., Ross, C. A., and Snyder, S. H. (1996) Science 273, 503-507[Abstract]
  58. Marin, M. C., Fernandez, A., Bick, R. J., Brisbay, S., Buja, L. M., Snuggs, M., McConkey, D. J., von Eschenbach, A. C., Keating, M. J., and McDonnell, T. J. (1996) Oncogene 12, 2259-2266[Medline] [Order article via Infotrieve]
  59. Kaneko, Y., and Tsukamoto, A. (1994) Cancer Lett. 97, 147-155
  60. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  61. Dolmethsch, R. E., Lewis, R. S., Goodnow, C. C., and Healy, J. I. (1997) Nature 386, 855-858[CrossRef][Medline] [Order article via Infotrieve]
  62. Flohe, L., Brigelius-Flohe, R., Saliou, C., Traber, M. G., and Packer, L. (1997) Free Radical Biol. Med. 22, 1115-1126[CrossRef][Medline] [Order article via Infotrieve]
  63. Mattson, M. P. (1998) Int. Rev. Neurobiol. 42, 103-168[Medline] [Order article via Infotrieve]
  64. Prehn, J. H. M., Jordan, J., Ghadge, G. D., Preis, E., Galindo, M. F., Roos, R. P., Krieglstein, J., and Miller, R. J. (1997) J. Neurochem. 68, 1679-1685[Medline] [Order article via Infotrieve]
  65. Keller, J. N., Kindy, M. S., Holtsberg, F. W., St. Clair, D. K., Germeyer, A., Steiner, S. M., Bruce-Keller, A. J., Hutchins, J. B., and Mattson, M. P. (1998) J. Neurosci. 18, 687-697[Abstract/Free Full Text]
  66. Nixon, R. A., Saito, K. I., Grynspan, F., Griffin, W. R., Katayama, S., Honda, T., Mohan, P. S., Shea, T. B., and Beermann, M. (1994) Ann. N. Y. Acad. Sci. 747, 77-91[Abstract]
  67. Liguri, G., Cecchi, C., Latorraca, S., Pieri, A., Sorbi, S., Degl'Innocenti, D., and Ramponi, G. (1996) Neurosci. Lett. 210, 153-156[CrossRef][Medline] [Order article via Infotrieve]
  68. Ito, E., Oka, K., Etcheberrigaray, R., Nelson, T. J., McPhie, D. L., Tofel-Grehl, B., Gibson, G. E., and Alkon, D. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 534-538[Abstract]
  69. Haug, L. S., Ostvold, A. C., Cowburn, R. F., Garlind, A., Winblad, B., Bogdanovich, N., and Walaas, S. I. (1996) Neurodegeneration 5, 169-176[CrossRef][Medline] [Order article via Infotrieve]
  70. Yan, S. D., Yan, S., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M. A., Perry, G., Godman, G. C., Nawroth, P., Zweier, J. L., and Stern, D. (1995) Nat. Med. 1, 693-699[Medline] [Order article via Infotrieve]
  71. Markesbery, W. R. (1997) Free Radical Biol. Med. 23, 134-147[CrossRef][Medline] [Order article via Infotrieve]
  72. Beal, M. F. (1995) Ann. Neurol. 38, 357-366[Medline] [Order article via Infotrieve]
  73. Benzi, G., and Moretti, A. (1997) Adv. Cell Aging Gerontol. 2, 129-160
  74. Kim, T.-W., Pettingell, W. H., Jung, Y.-K., Kovacs, D. M., and Tanzi, R. E. (1997) Science 277, 373-376[Abstract/Free Full Text]
  75. Jordan, J., Galindo, M. F., and Miller, R. J. (1997) J. Neurochem. 68, 1612-1621[Medline] [Order article via Infotrieve]
  76. Weidemann, A., Paliga, K., Durrwang, U., Czech, C., Evin, G., Masters, C. L., and Beyreuther, K. (1997) Nat. Med. 3, 328-332[Medline] [Order article via Infotrieve]
  77. Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8208-8213[Abstract/Free Full Text]
  78. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., and Younkin, S. (1996) Nature 383, 710-713[CrossRef][Medline] [Order article via Infotrieve]
  79. Querfurth, H. W., and Selkoe, D. J. (1994) Biochemistry 33, 4550-4561[Medline] [Order article via Infotrieve]
  80. Gabuzda, D., Busciglio, J., Chen, L. B., Matsudaira, P., and Yankner, B. A. (1994) J. Biol. Chem. 269, 13623-13628[Abstract/Free Full Text]
  81. Palmert, M. R., Usiak, M., Mayeux, B., Raskind, M., Tourtellotte, W. W., and Younkin, S. G. (1990) Neurology 40, 1028-1034[Abstract]
  82. Urakami, K., Takahashi, K., Saito, H., Okada, A., Nakamura, S., Tanaka, S., Kitaguchi, N., Tokushima, Y., and Yamamoto, S. (1992) Acta Neurol. Scand. 85, 343-346[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.